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 Abstract - Mature Large Granular lymphocytes (LGL) 
disorders include a spectrum of conditions, ranging from 
polyclonal to clonal indolent and/or overt leukemic LGL 
proliferations. Most cases are represented by clonal 
expansions of TCRα/β+ LGL displaying a CD8+ phenotype 
with expression of cytotoxic T-cell antigens (CD57, CD16, 
TIA-1, perforin and granzyme B). Proliferations of CD3-
CD16+ NK cells with a restricted patter of NK receptors are 
less common, usually comprising 15% of the cases. Main 
features are cytopenias, splenomegaly and autoimmune 
phenomena. Morphology, immunophenotyping and 
molecular analyses are crucial to establish a correct 
diagnosis of disease. According to the 2008 WHO 
classification, two separate entities account for the majority 
of cases, T-LGL leukemia and Chronic Lymphoproliferative 
Disease of NK cell (this latter still provisional). Although 
these disorders are characterized by the expansion of 
different cells types i.e. T and NK cells, with specific genetic 
features and abnormalities, compelling evidence supports the 
hypothesis that a common pathogenic mechanism would be 
involved in both disorders. As a matter of fact, a foreign 
antigen driven clonal selection is considered the initial step in 
the mechanism ultimately leading to generation of both 
conditions.  In this chapter we will discuss recent advances 
on the pathogenesis of chronic T and NK disorders of 
granular lymphocytes, challenging the current WHO 
classification on the opportunity to separate T and NK 
disorders, which are likely to represent two sides of the same 
coin. 
 




I.  INTRODUCTION 
 
 Large Granular lymphocytes (LGL) disorders 
include a spectrum of conditions, ranging from polyclonal 
to clonal indolent and/or overt leukemic LGL 
proliferations. Since its original description, large granular 
lymphocyte leukemia (LGLL) has represented a matter of 
controversy, as to whether we are dealing with a lymphoid 
malignancy or with an exaggerated reactive T-cell process 
[1-3]. LGLL is actually defined as a clonal chronic 
lymphoproliferative disorder that can be phenotypically 
subdivided into T-cell LGLL and natural killer LGLL. 
Although derived from distinct cell lineages, both 
subtypes are morphologically similar and are 
characterized by the accumulation of large granular 
lymphocytes that correspond to a mature cytotoxic 
effector type.  Accordingly, the 2008 WHO considers NK 
and T lymphocytes disorders (i.e., NK-CLPD and T-
LGLL) as two different and well separated entities [4,5].  
However, the WHO classification relies on different 
lineage features of T and NK cells, not taking into account 
putative common pathogenic mechanisms and clinical 
features. As a matter of fact, chronic NK and T cell 
expansions display a similar morphology and, on clinical 
grounds, in both types of patients cytopenias and other 
comorbidities are often associated [6,7]. Furthermore, the 
treatment in T-LGLL and NK-CLPD patients is very 
similar, entailing an immunosuppressive regimen or 
careful observation of chronic lymphocytosis [8]. A series 
of recent new observations, in addition to the previously 
acquired evidence, point to the suggestion that chronic 
LGL disorders should be more properly included within 






 The evidence of a granular lymphocytosis greater 
than 2,000/l lasting for more than 6 months has been 
generally accepted as the most relevant criteria for the 
diagnosis of disease [7], considering that normally 
circulating LGL counts are 0.25 x 10
9
/L [8]. This figure 
obviously requires additional evaluation of 
immunophenotyping and molecular analyses. This is 
particularly relevant when only some of the above criteria 
might be present. On blood films, the LGL nucleus is 
typically round with condensed, mature chromatin; the 
cytoplasm is pale, where randomly distributed azurophilic 
granules are easily detectable [7,8].  BM involvement by 
chronic LGL disorders is often subtle and difficult to 
identify, even when apparent in the PB [9].  
 In most cases, flow cytometry immunophenotyping 
defines a CD3+ LGLL, which usually express the TCR 
α/β+, CD2+, CD4-, CD8+, CD16+, CD57+, CD45RA+, 
CD122+ (p75 IL-2R), CD25- (p55 IL-2R) phenotype.  
CD5 and CD7 are weakly expressed or negative; CD56 is 
rarely positive and it has been claimed to be associated 
with a more aggressive clinical course [7]. These cells 
usually display a cytotoxic phenotype corresponding to 
that of a fully differentiated mature cytotoxic T 
lymphocyte (CD45RA+, CD27-, CD28-, CD62L-, CCR7) 
[10].  Most cases represent expansions of T cells bearing 
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the TCR αβ+ while only a minority is derived from 
TCRγδ+ cells bearing a Vγ9+/Cδ2+ or a Vγ9-/Cδ1 
phenotypic profile with TCRγ monoclonal restriction [11]. 
The expression of the inhibitory complex CD94/NKG2A, 
belonging to NK receptor, in these cells seems to correlate 
with a less aggressive behavior of proliferation [12]. Flow 
cytometry analysis with MoAb against the various Vβ 
regions of the TCR allows to establish the clonality of the 
LGLs by showing the preferential use of one or two TCR-
Vβ segments [13]. These techniques should be applied to 
all suspected cases and are useful in those patients in 
whom the absolute LGL count is not significantly 
increased. 
 Formal proof that we are dealing with a T-LGL is 
provided by the establishment of clonality through gene 
rearrangement studies [7-8], these techniques allowing to 
distinguish LGL proliferations as a neoplastic disease or 
reactive lymphocytosis. Methods used to determine TCR 
gene rearrangement are polymerase chain reaction (PCR) 
and Southern blotting. While Southern blotting has fewer 
false negative and false positive results,  PCR is a more 
sensitive technique for detection. Also, PCR is considered 
more user friendly in that it is less labor-intensive and 
does not require high-molecular weight DNA, which 
allows for DNA to be used from paraffin-embedded 
tissues when fresh or frozen samples are not available 
[14]. 
 CD3- LGLL are characterized by the 
CD16+CD56+CD45RA+CD122+CD25- phenotype. 
CD57 antigen is usually weakly detectable. CD56 antigen 
is normally expressed by LGL, although some negative 
cases are reported. No clinical correlation with this marker 
has been performed, although CD56 negative cases seem 
to be more frequently associated to cytopenia.  CD94 
antigen is found at high density on patients’ NK cells; this 
antigen is usually associated with the inhibitory subunit 
NKG2A, although in some cases the association 
CD94/NKG2C has been reported [13]. Patients’ NK cells 
characteristically express functional β and γ chains of IL-
2/IL-15 receptor, which are strictly related to the role of 
these cytokines in the pathogenesis of disease [15]. 
Expression of NK receptors, mostly represented by KIR, 
is altered in patients with CLPD-NK. A restricted pattern 
of KIR expression has usually been reported in these 
patients, which is characterized either by a dominant 
expression of a relevant KIR, or by a lack of KIR 
expression  [16,17]. NK-LGL cells are not equipped with 
the TCR and therefore clonality cannot be determined by 
the rearrangement of TCR genes. In these cases a KIR 
restricted pattern of expression has been considered as a 
marker of clonality [16]. In addition, the demonstration of 
somatic STAT3 mutations [18-20] may represent a useful 
tool in the diagnosis of disease, although not easily 




Figure 1. See text for more details. 
Abbreviations. PB = peripheral blood; LGL = large granular lymphocytes; TCR = T cell receptor; KIRs = Killer Ig-like receptors. 
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III. CLINICAL FEATURES 
 
 The disease usually affects older people (mean 60 
years). It is more common in Eastern than in Western 
countries. The disease runs asymptomatic in nearly 30% 
of cases, with lymphocytosis representing the only 
observed hematological abnormality [1-3]. These 
asymptomatic patients may have other associated 
conditions; among these, RA is the most commonly 
reported co-morbidity condition [8, 21] but several other 
connective tissue diseases such as systemic lupus 
erythematosus have been reported to be associated with T-
cell LGL leukemia. Hematological conditions are another 
well represented group including monoclonal 
gammopathies, multiple myeloma, myelodysplastic 
syndromes, myelofibrosis, Hodgkin’s and non Hodgkin’s 
lymphomas [8, 21]; non-hematological neoplasms have 
also been reported in association with LDGL. The term of 
T-cell clonopathy of unknown significance (TCUS) has 
been suggested to designate these asymptomatic patients 
[22]. Symptomatic patients frequently present with fever 
due to infections or mouth lesions, often related to 
neutropenia. Weakness due to anemia represents another 
relevant finding. B-related symptoms (fever, night sweats, 
weight loss) are observed in nearly 25% of cases. Another 
intriguing association has been found between LDGL and 
pulmonary hypertension, with documented infiltration of 
the lung by GL [23].  Up to a half of the patients have 
splenomegaly, around 20% of cases present skin lesions 
and only a minority have hepatomegaly; 
lymphadenopathy is rare.  
 Most CLPD-NK patients are asymptomatic, and the 
disease has a chronic indolent clinical course, similar to 
that reported for patients with T LGL leukemia [24]. 
Associated conditions are reported even for CLPD-NK, 
including pure red cell aplasia, vasculitic syndromes, solid 
and hematologic tumors, splenectomy, neuropathy and 
autoimmune disorders [8,24]. Recently in patients with 
chronic myeloid leukaemia an association between 
treatment with dasatinib and the development of the 
lymphoproliferative disease has been reported, the 
hypothesis having been suggested that the CLPD-NK 
might have a beneficial therapeutical effect on Ph+ 
leukemic cells [25]. Cytopenia (either neutropenia and 
anemia) are quite common. The leukocyte count may be 
normal or slightly elevated but in most patients there is an 
increase in circulating LGL, even without having an 
absolute lymphocytosis; some cases are lymphopenic. In 
discrete patients lymphocytosis develops after 
splenectomy. Lymphoadenopathy, hepatomegaly, 
splenomegaly and cutaneous lesions are uncommon [24]. 
Occasionally, patients present with a slowly progressive 
increase of peripheral blood NK cells and with organ 
involvement. In rare cases the disease transforms to 
aggressive NK cell leukemia and cases with EBV positive 
NK cells tend to evolve [25].  Several cases with a 





 Disease may run asymptomatic for many years in the 
majority of patients, whereas in other cases therapy is 
needed, usually for cytopenia-related manifestations. The 
percentage of patients who require therapy at some time 
during the disease ranges from 30 to 70%, according to 
different series [21].  In one of the largest published 
multicenter study including 151 cases, coordinated by our 
institution, mortality after 4 year follow-up was 20% and a 
median survival greater than 10 years [6].  Most deaths are 
due to sepsis and rarely occur due to disease progression. 
 Indications for treatment include severe and 
symptomatic neutropenia, transfusion dependent anemia 
or thrombocytopenia as far as progressive disease (i.e., 
appearance of organomegaly,  B symptoms and rapidly 
LGL raising counts). Correction of cytopenias with 
therapy may be achieved without eradication of the clone, 
which often persists even after treatment. 
Immunomodulatory drugs, such as methotrexate (10 
mg/m
2
/weekly), cyclosporine A (5-10 mg/kg/day) or low 
dose cyclophosphamide (50 to 100 mg/day) have been 
commonly used [27-30].  Corticosteroids may be useful as 
a part of the initial treatment to accelerate response and 
growth factors are often used. Adverse events are not 
severe and are more common with cyclosporine A, 
particularly in elderly patients. Splenectomy may be 
considered as an adjuvant in patients with relevant 
splenomegaly and refractory cytopenias [31]. Once 
patients with LGL leukemia begin treatment, the regimen 
should not be altered for a period of 4 months, and they 
must be closely observed through complete blood counts 
[8]. After this time point, a hematological complete 
response is considered achieved when blood counts reveal 
platelets >150 x10
9
/L, ANC >1.5 x 10
9
/L, lymphocytes <4 
x 10
9
/L, and hemoglobin >12 g/dL. Complete molecular 
remission is reached when the T-cell clone is no longer 
detectable through PCR analysis [8]. Partial response is 
considered when overall blood counts improve but the 
ANC has not achieved levels > 500 cells/μL, still leaving 
the patient at potential risk for secondary infections. 
Should an improvement not be achieved after 4 months of  
continued treatment, then one of the alternative therapies 
described above should be taken into account. 
Chemotherapeutic agents currently being tested in 
cutaneous T-cell lymphoma (CTCL) and peripheral T-cell 
lymphoma (PTCL), such as gemcitabine, liposomal 
doxorubicin as well as the purine analogs, such as 
fludarabine, cladribine and nelarabine, represent possible 
new agents to be considered for symptomatic LGL 
disorders [8, 21]. Purine analogs have been only used in 
few patients with response rates of 40 to 67% for 
pentostatin, fludarabine alone or in combination. The use 
of these agents should be considered for young patients as 
they allow the achievement of good remissions, including 
the reduction of bone marrow infiltration.  
Monoclonal antibodies anti-CD52 (Campath-1H), 
anti-CD122 and anti-CD2 are being incorporated in
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*Data summarize results reported in Koskela et al [18], Jerez et al [20], Fasan et al [56], Teramo et al [48], Sekiguchi et al [57];  
** Data summarize results reported in Rajala et al [21];  
§ Data summarize results reported in Jerez et al [20], Sekiguchi et al [57], Gattazzo et al, submitted;   
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^ Data summarize results reported in  Gattazzo et al, submitted;  
° Data summarize results reported in Loughran et al [45];  
°°Data summarize results reported in Sokol et al  [46]. 
the therapeutic scenario [8,21]. Good responses have been 
obtained in patients with symptomatic T-LGL leukemia 
and CLPD-NK with the use of RAS farnesyltransferase 
inhibitor (FTI), tipifarnib (Zarnestra®, Johnson & 
Johnson), according to the findings of a constitutively 
active signaling of the Ras/MAPK/ERK pathway [32]. 
Recently, the efficacy of extracorporeal photopheresis has 
been evaluated in 5 refractory/relapsed patients with LGL 
leukemia, with 2 of 5 patients achieving a CR [33]. In 
addition, the proteasome inhibitor bortezomib has been 
reported to display anticancer activity against aggressive 
NK leukemia and extranodal NK/T cell lymphoma in vitro 
and in vivo, opening new therapeutical prespectives for 




V. ARE T-LGLL AND CLPD-NK REALLY TWO 
DIFFERENT DISORDERS? 
 
 During infection exposure or antigen stimulation, 
LGLs undergo proliferation by many thousands of times 
upon priming by target cells, and at a later time after 
antigen clearance, are selectively eliminated by a process 
called activation induced cell death (AICD) [34]. The 
etiology of chronic LGL proliferations is largely unknown 
in most cases. This is consequent to the fact that not a 
single specific agent can establish the LGL proliferation, 
which instead is likely due to the expression of an 
erroneous management of a foreign agent. In other words, 
different agents are supposed to induce the disease 
through a common pathogenetic mechanism. Crucial 
cornerstones for disease development have been recently 
identified. A number of reports strongly support the role 
of a chronic/persistent antigenic stimulation by an auto- or 
foreign infective antigen as an initial event [36-38]. This 
would lead to the expansion of a fully differentiated 
effector/cytotoxic LGL, which is not eliminated due to an 
impairment on the apoptotic pathway [39]. Multiple cell 
survival pathways, including JAK2/STAT3, sphingolipid 
signaling, RAS/MEK/ERK, and SFK/PI3K/Akt, have 
been found to be constitutively activated in LGL leukemia 
patients (reviewed in [40]). Some of these altered 
pathways seem more correlated with T-type, others with 
NK cell type of proliferation, whereas others are common 
of both T and NK cell proliferation. A biology approach 
identified IL-15 and PDGF as master survival signaling 
switches that may have a profound effect on all known 
deregulations in T-LGL leukemia [39]. 
  However, if both disorders share the feature of a 
persistent antigenic stimulation, it is reasonable to think 
that in the same patient both T and NK cell can be under 
antigenic pressure. Consequence of this finding rests on 
the fact that growth mechanisms shared by T and NK cells 
represent the cornerstone for the genesis of a LGL 




VI. IS THERE A COMMON ANTIGEN SHARED 
BETWEEN THE TWO DISORDERS? 
 
 It has been suggested that bone marrow, which is 
frequently, although minimally, involved in LGL 
proliferation patients, represents the setting where the 
putative inciting antigen could reside and dendritic cells 
(DC) have been indicated to play a role as presenting cells 
and, perhaps, as IL-15 producers in these patients [41]. 
Data pointing to a putative pathogenic role for some virus, 
in particular  herpes virus [42, 43]  and retroviral agents 
have been reported [44-46]. The evidence that sera from a 
series of patients from Europe and USA suffering from 
LGLL or CLPD-NK reacted with the recombinant human 
T lymphotropic virus (HTLV) env protein p21E suggests 
that exposure to a protein containing homology to BA21 
may be important in the pathogenesis of these 
lymphoproliferative disorders [45-46]. Taken together, all 
these data point to a putative immune system’s inability to 
clear the proposed virus, favoring the survival of LGL 
leukemia cells [47]. 
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VII. WHICH EVIDENCE OF ANTIGEN 
PERSISTENCE? 
 
 Two theories, not necessarily mutually exclusive, 
have polarized the investigations on the pathogenesis of 
chronic LGL disorders, possibly representing two 
different steps of the natural history of disease. The first 
hypothesis considers the proliferation and accumulation of 
a transformed T or NK cell originated upon acquired 
intrinsic molecular defect (for example as a mutation [18-
20] or other inhibitory mechanisms [48]). Alternatively, 
they might represent the expression of a global 
dysregulation of cytotoxic T or NK cell repertoire 
homeostasis because of persistent antigenic drive in 
combination with immunogenetic factors favoring 
persistent cell expansions [49]. This latter theory is 
supported by the phenomenon of clonal drift, reported in 
nearly 50% of LGLL patients, which is characterized by 
the change of dominant clone during time [50].  Taken 
together, these results are consistent with the evidence that 
T-LGLL may involve multiple clones occurring either 
concurrently or even serially. Our group recently 
demonstrated the presence of monoclonal T cell 
populations in 48% of cases in a cohort of 42 patients with 
KIR restricted NK-CLPD. Even more intriguing is the 
finding that these monoclonal populations can be detected 
not only at the time of diagnosis, but in some cases they 
can occur during the natural history of disease, indicating 
that the association of T and NK proliferations is much 
more frequent that initially thought. The T cell clone can 
eventually became so relevant to be dominant, leading to 
the shift from NK-CLPD to T-LGLL [Gattazzo et al,  
submitted].  Both these observations indicate that cells are 
under antigenic pressure, suggesting that the putative 
antigen is likely to persist for many years and possibly for 
the lifelong of patients. This finding points to the 
relevance of a long lasting follow up of these patients and 
the possibility that a sudden worsening of clinical features 
even in indolent cases could never be ruled out, as 




VIII. IS  STAT3  ACTIVATION A CENTRAL POINT? 
 
 The constitutive activation of JAK/STAT pathway 
has been claimed to be involved in the development of 
several human cancers, including hematologic neoplasms 
(acute myeloid leukemias, Sezary syndrome, multiple 
myeloma) [52-54]. In T-LGLL Epling-Burnette et al 
reported that LGL from patients constitutively express 
high levels of activated STAT3 as compared to PBMC of 
healthy individuals [55].  They also showed that STAT3 
activation contributes to Fas resistance resulting in 
abnormal survival of leukemic LGL and is also 
responsible of the over-expression of the anti-apoptotic 
protein Mcl-1 [55].  We recently confirmed that over-
expression and activation of STAT3 is a constitutive 
feature present in all LGLL patients and extend this 
observation to the comprehension of the mechanisms 
leading to the constitutive activation of STAT3 in these 
patients [48]. In fact, we provided evidence that the IL-6 
produced in vivo by autologous monocytic cells represents 
a cytokine that is central for STAT3 upregulation.  We 
also demonstrated that the lack of inhibitory signals 
counterbalancing STAT3 activation, mediated by 
epigenetic inhibition of SOCS3, plays a role in the 
persistence of this activation pathway [48]. Recently, in 
vivo activation of STAT3 has been reported also in 
patients with CLPD-NK ([19] and Zambello, unpublished 
data), indicating that STAT3 activation is a unifying 





IX. HOW DOES DISEASE PROGRESS? 
 
Recently, it has been observed that recurrent somatic 
missense mutations of STAT3 (more often Y640F and 
D661Y) might be demonstrated in one third of patients 
with LGLL [18].  The same Authors updated their case 
study in more than 100 LGLL patients confirming that 
STAT3 mutations were also detectable in nearly one third 
of patients with CLPD-NK [19]. These data have also 
been confirmed by other groups, although the percentage 
of mutated cases ranged from 22 to 77% [48, 56-57]. It 
has been suggested that mutated STAT3 still retains its 
physiologic ability to stimulate some target genes. Jerez et 
al. also suggested that STAT3 mutation can be helpful in 
discriminating true leukemic from possibly reactive 
conditions [19]. This conclusion however should be 
viewed with caution. As a matter of fact, whereas STAT3 
activation is indeed a constitutive mechanism in all T-
LGLL patients [48, 55], STAT3 mutations are reported 
only in a fraction of cases, despite the presence of 
monoclonal rearrangement of TCR was shown in all cases 
[18, 19].  In addition, considering each single patient, 
STAT3 mutated LGL have been shown to account for 
only a minority of the entire monoclonal LGL population 
[19].  Furthermore, in the STAT3 mutated patients, 
consistent with unmutated cases, we observed a high 
expression of P-STAT3 and IL-6, associated to SOCS3 
down-regulation, ruling out any specific peculiarity for 
these patients [48].    Finally, by incubating pathological 
LGL with the downstream STAT3 selective inhibitor 
STA-21 (a novel synthetic inhibitor of STAT3 
dimerization, DNA binding, and STAT3-dependent 
luciferase reporter activity) apoptosis was induced in both 
CLPD-NK or T-LGLL, irrespective of the mutational 
status [19]. 
 According with the above quoted considerations, we 
suggest that the acquisition of STAT3 mutations might be 
an event occurring late during the natural history of 
disease, certainly later than the establishment of clonality. 
This event is likely to represent a marker of the 
progression of disease, defining in patients with T-LGLL 
and CLPD-NK a common specific clinical and pathogenic 
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pattern driven by a shared genetic lesion, irrespective of 




X.  CONCLUSION 
 
 Chronic LGL proliferations can arise from either 
cytotoxic T-cell lymphocytes or NK-cell lymphocytes. 
Individuals with either type of cell proliferations have a 
good prognosis and respond quite well to current available 
immunosuppressive therapies.  To get insight into the 
characteristics of LGL disorders, it is mandatory to fully 
understand the development pathways of normal LGL. 
Until the distinctive features between cytotoxic T and NK 
cells are notcompletely elucidated, the shared altered 
pathways and clinical behavior strongly support the 
opportunity of merging both entities in one disease 
category, as we initially suggested under the definition of 
lymphoproliferative disease of granular lymphocytes [1]. 
DNA profiling and Next Generation Sequencing using 
purified normal and pathological T and NK cells will help 
to address this issue and would likely help in elucidating 
the differences of clinical behavior between cytotoxic T 
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